---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-007965"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:31:27.491766+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lantheus Q4 revenue $391M (+10.5%); GAAP EPS $(0.17), adj. EPS $1.59; FY25 guide $1.55B-$1.61B

## Summary
- Q4 revenue $391.1M (+10.5% YoY); PYLARIFY $266M (+15.7%), DEFINITY $86.2M (+17.9%).
- GAAP fully diluted EPS $(0.17) vs $1.47 prior; adj. EPS $1.59 (-9% YoY).
- Agreements to acquire Life Molecular (Alzheimer's radiodiagnostic) and Evergreen Theragnostics (manufacturing), expected H2 2025.
- CMS final 2025 OPPS rule grants separate payment for PYLARIFY and other diagnostic radiopharmaceuticals.
- FY 2025 revenue guidance $1.545B-$1.610B; adjusted EPS guidance $7.00-$7.20.

## SEC filing metadata
- accession: 0001628280-25-007965
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000162828025007965/0001628280-25-007965-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000162828025007965/lnth-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-007965
- JSON: https://secwatch.observer/filing/0001628280-25-007965.json
- Plain text: https://secwatch.observer/filing/0001628280-25-007965.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.